The way you think, the way you behave, the way you eat, can influence your life by 30 to 50 years.

-Deepak Chopra

 

PNA Spotlight: Dr. Manish Aghi

This month the PNA Spotlight focuses on Dr. Manish K. Aghi.Dr. Manish Aghi is a neurosurgeon specializing in brain tumors at UCSF Medical Center. He cares for adult patients with a wide range of conditions, including astrocytomas and anaplastic astrocytomas, oligodendrogliomas, glioblastomas, meningiomas and pituitary adenomas. As principal investigator at the UCSF Brain Tumor Research Center, his interests include glioblastoma angiogenesis, mechanisms of glioblastoma resistance to anti-angiogenic therapy and experimental glioblastoma therapies such as cancer-killing viruses.
Professor Aghi earned his medical degree and a doctoral degree in neurosciences from Harvard Medical School. He completed a residency in neurosurgery at Massachusetts General Hospital. He is a member of the Society for Neuro-Oncology, American Association of Neurological Surgeons, Congress of Neurological Surgeons and Pituitary Network Association. Among his honors are the Preuss and Mahaley awards from the American Association of Neurological Surgeons, and the Ronald L. Bittner Award, Synthes Skull Base Award and Integra Foundation Award from the Congress of Neurological Surgeons.
His answers follow.

Read more

PNA Medical Corner: Pituitary Centers of Excellence

This month the PNA Medical Corner focuses on an article co-authored by several members and colleagues of the PNA: Drs. Chanson, Kaiser, Laws, van der Lely, and Melmed. It addresses a topic that PNA has sought to promote for decades: the designation of Pituitary Centers of Excellence, where patients can get highly specialized care

Link: https://pubmed.ncbi.nlm.nih.gov/37640885/

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

Read More

Featured News and Updates

The FDA has approved NGENLA (somatrogon-ghla)

The FDA has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.

See the Press Release here>

News Articles September 2025

News Articles September 2025

Community remembers young pituitary patient with a fundraiser, scholarship

An article in the Utica Observer Dispatch tells the story of a fifth grader named Olivia Sacco, who passed away last year from septo-optic dysplasia. Her condition meant she was born with an underdeveloped pituitary gland and had to be on hormone replacement for her entire young life. Recently the community held a lemonade stand to raise money for a scholarship in her honor. Read more here: https://www.uticaod.com/story/news/local/2025/08/26/olivias-memory-lives-on-in-hearts-of-community/85834655007/

 South Korean government cracks down on misuse of growth hormone

South Korea’s Ministry of Food and Drug Safety has launched an investigation into medical providers and pharmacies to crack down on misuse of growth hormones. Specifically, they are hoping to curb prescriptions of hormones and steroids given with promises to increase a child’s height or improve muscle mass. Read more: https://biz.chosun.com/en/en-science/2025/08/25/BMBNGXXUGRBJ3FK5KMDNMZEJMY/

Patient Story: 20-year-old pituitary tumor survivor races for a cure

A young woman in the UK is doing the Walk of Hope to raise money for brain tumor research. Esme Smith was first diagnosed at 11 years old with a golf ball-sized craniopharyngioma and successfully underwent surgery the following year. Read  more: https://www.inyourarea.co.uk/news/hampshire-brain-tumour-survivor-takes-on-25-5-mile-challenge-to-find-a-cure

Brain tumor detection: optimized deep learning

A study published on the website Nature.com looks at optimized deep learning for brain tumor detection.  The authors explore a hybrid approach with “VGG16, an attention mechanism, and optimized hyperparameters to classify brain tumors into different categories as glioma, meningioma, pituitary tumor, and no tumor”. Read more: https://www.nature.com/articles/s41598-025-04591-3#Sec18

Research Articles

September 2025 Research Articles

Pituitary Tumors

Long-term behaviour of non-functioning pituitary microadenomas: experience from a tertiary care centre in Romania.

Iftimie ME, Burcea IF, Dobre R, Pigni S, Prodam F, Poiană C.Front Endocrinol (Lausanne). 2025 Aug 11;16:1613239. doi: 10.3389/fendo.2025.1613239. eCollection 2025.

 

Clinical characteristics and surgical approach for pituitary granular cell tumors: a case series of six patients and literature review.

Liu J, Zhang W, Huang Q, Ye X, Huang G.Front Oncol. 2025 Aug 11;15:1490783. doi: 10.3389/fonc.2025.1490783. eCollection 2025.

 

Autoimmune thyroid disease and pituitary adenoma in a female patient with 18p deletion syndrome: a case report and review of the literature.

Ye J, Shu Y, Wang M, Luo H, Liang W, Lu Q, Mei W, Deng J.BMC Endocr Disord. 2025 Aug 25;25(1):199. doi: 10.1186/s12902-025-02017-9.

 

Prospectively assessed hypothalamic-pituitary dysfunction after proton therapy in adults with head and neck, skull base and brain tumors.

Bouter J, Azemar N, Vela A, Dutheil P, Lesueur P, Stefan D, Reznik Y, Thariat J.Sci Rep. 2025 Aug 24;15(1):31085. doi: 10.1038/s41598-025-16960-z.

 

Pituitary Surgery

Alterations of Brain Structural and Functional Connectivity Networks and Its Correlations With Cognitive Function in Patients With Hypothalamic Syndrome Following Craniopharyngioma Resection.

Li S, Ma J, Tong Z, Jiang H, Li L, Zhang Y.Brain Behav. 2025 Aug;15(8):e70730. doi: 10.1002/brb3.70730.

 

Isolated syndrome of inappropriate antidiuresis (SIAD) after Transphenoidal surgery of a non-functioning pituitary adenoma: clinical case report.

Quilismal N, Risso M, Agüero P, Lima R, Garagorry F, Centurion D, Pineyro MM.Oxf Med Case Reports. 2025 Aug 25;2025(8):omaf152. doi: 10.1093/omcr/omaf152. eCollection 2025 Aug.

 

Diagnostics

A Web-Deployed, Explainable AI System for Comprehensive Brain Tumor Diagnosis.

Aksoy S, Demircioglu P, Bogrekci I.Neurol Int. 2025 Aug 4;17(8):121. doi: 10.3390/neurolint17080121.


Machine learning-based models and radiomics: can they be reliable predictors for meningioma recurrence? A systematic review and meta-analysis.

Niroomand B, Mohammadzadeh I, Hajikarimloo B, Habibi MA, Mohammadzadeh S, Bahri AM, Bagheri MH, Albakr A, Karmur BS, Borghei-Razavi H.Neurosurg Rev. 2025 Aug 27;48(1):623. doi: 10.1007/s10143-025-03744-2.


From Detection to Diagnosis: An Advanced Transfer Learning Pipeline Using YOLO11 with Morphological Post-Processing for Brain Tumor Analysis for MRI Images.

Chourib I.J Imaging. 2025 Aug 21;11(8):282. doi: 10.3390/jimaging11080282.

 

Hormonal Health
Oxytocin, Vasopressin and Stress: A Hormetic Perspective.

Nazarloo HP, Kingsbury MA, Lamont H, Dale CV, Nazarloo P, Davis JM, Porges EC, Cuffe SP, Carter CS.Curr Issues Mol Biol. 2025 Aug 7;47(8):632. doi: 10.3390/cimb47080632.

 

Acromegaly

Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy With a Linear Accelerator (LINAC) for Acromegaly Remission: Clinical Experience From a Tertiary Neurological Center in Latin America.

Santos-Santos RI, Flores-Vázquez JG, Rodriguez-Hernandez LA, Fuentes-Calvo I, Rodríguez-Hernández IA, Mateo Nouel EJ, Villanueva-Castro E, Muñuzuri-Camacho MA, Palacios-Rodríguez RA, Wong-Achi X, Villalobos-Díaz R, Moncada-Habib T, Moreno-Jiménez S, Gutierrez-Aceves GA, Portocarrero-Ortiz LA.Cureus. 2025 Jul 24;17(7):e88708. doi: 10.7759/cureus.88708. eCollection 2025 Jul.

Cushing’s

Relapse of Cyclic Cushing Syndrome With a 19-Year Remission: Potential Involvement of COVID-19 in the Relapse.

Takayama K, Mukai K, Motoda S, Ose N, Obata Y, Shimomura I.JCEM Case Rep. 2025 Aug 22;3(10):luaf189. doi: 10.1210/jcemcr/luaf189. eCollection 2025 Oct.

 

Copyright © 2024 Pituitary Network Association All rights reserved.

Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.

Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email [email protected]

You are receiving this Newsletter because you have shown interest in receiving information about our activities.

If you do not want to receive any more emails from PNA, Unsubscribe.